← Leaderboards
Gregory Paul Marshall
Onevax, Llc
$1,464,833
Attributed
$1,464,833
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $719.7K · FY2014–18$1M$750K$500K$250K$0
'14
'15
'16
'17
'18
Funding mix
By agency
NIH$1,464,833 · 7
By mechanism
R43$1,091,399 · 5
R21$255,617 · 1
R41$117,817 · 1
Top collaborators
No co-investigators on record.
Others in their field
Top investigators on “Innovation”
- David R. Weir · University Of Michigan At Ann Arbor$382,307,654
- Eric Jeffrey Topol · Cleveland Clinic Lerner Col/Med-Cwru$319,874,172
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$311,654,401
- Richard A Gibbs · Baylor College Of Medicine$300,634,418
- Gerald T Nepom · Benaroya Research Inst At Virginia Mason$298,740,071
- Judith S. Currier · University Of California Los Angeles$271,752,220
Research focus
InnovationImmuneImmune SystemInbred Nod MiceCellsHeart DiseasesDiabeticGlucose MetabolismImmune ToleranceImmunityAffectCd3 AntigensCollaborationsHealth Care CostsComplexBeta CellAmericanDiabetes MellitusFloridaDiagnosisAutoimmune DiseasesAutoimmune ProcessAutoimmune ResponsesInsulin
Grant awards (8)
Development of a dual microparticle platform vaccine system encapsulating immunomodulatory agents and antigen for the amelioration of type 1 diabetes$221,331
R43 · FY2018 · AI · contact PI
Biomaterial-Based Delivery of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes$195,808
R43 · FY2018 · DK · contact PI
Delivery of biomaterial-conjugated regulatory T Cells for the amelioration of Type 1 Diabetes$127,740
R21 · FY2018 · AI · contact PI
A novel biomaterial-based therapy utilizing auto-antigen and adjuvant for the amelioration of Type 1 Diabetes$238,328
R43 · FY2017 · AI · contact PI
Biomaterial-based delivery of Interleukin-2 to Regulatory T Cells for the amelioration of Type 1 Diabetes$235,720
R43 · FY2017 · AI · contact PI
Delivery of biomaterial-conjugated regulatory T Cells for the amelioration of Type 1 Diabetes$127,877
R21 · FY2017 · AI · contact PI
Therapeutic Administration of Suppressor of Cytokine Signaling Mimetics to Ameliorate Type 1 Diabetes$117,817
R41 · FY2017 · AI · contact PI
A novel biomaterial-based therapy to prevent type 1 diabetes$200,212
R43 · FY2014 · DK · contact PI